LENZ Therapeutics, Inc.

    Jurisdiction
    United States
    ISIN
    US52635N1037 (LENZ)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    4 / 9

    Profile

    LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €4.31M
    Gross margin
    99.8%
    EBIT
    -€53.38M
    EBIT margin
    -1,239.2%
    Net income
    -€45.14M
    Net margin
    -1,048.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €42.84M +894.6% -€59.54M +31.9%
    €103.68M +142.0% -€5.24M -91.2%
    €175.31M +69.1% €44.99M -958.9%

    Dividends

    Last dividend amount
    $1.03
    Ex date

    Earnings Calls

    Latest earnings call: May 11, 2024

    Add to watchlist

    Notifications